Unstable angina / non ST elevation myocardial infarction treatment: Difference between revisions

Acute Coronary Syndrome Main Page
	Unstable angina / NSTEMI Microchapters
Home
Patient Information
Overview
Classification
Pathophysiology
Unstable Angina
Non-ST Elevation Myocardial Infarction
Differentiating Unstable Angina/Non-ST Elevation Myocardial Infarction from other Disorders
Epidemiology and Demographics
Risk Stratification
Natural History, Complications and Prognosis
Special Groups
Women
Heart Failure and Cardiogenic Shock
Perioperative NSTE-ACS Related to Noncardiac Surgery
Stress (Takotsubo) Cardiomyopathy
Diabetes Mellitus
Post CABG Patients
Older Adults
Chronic Kidney Disease
Angiographically Normal Coronary Arteries
Variant (Prinzmetal's) Angina
Substance Abuse
Cardiovascular "Syndrome X"
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Blood Studies
Biomarkers
Electrocardiogram
Chest X Ray
Echocardiography
Coronary Angiography
Treatment
Primary Prevention
Immediate Management
Anti-Ischemic and Analgesic Therapy
Cholesterol Management
Antitplatelet Therapy
Antiplatelet therapy recommendations
Aspirin
Thienopyridines
Glycoprotein IIb/IIIa Inhibitor
Anticoagulant Therapy
Additional Management Considerations for Antiplatelet and Anticoagulant Therapy
Risk Stratification Before Discharge for Patients With an Ischemia-Guided Strategy of NSTE-ACS
Mechanical Reperfusion
Initial Conservative Versus Initial Invasive Strategies
PCI
CABG
Complications of Bleeding and Transfusion
Discharge Care
Medical Regimen
Post-Discharge Follow-Up
Cardiac Rehabilitation
Long-Term Medical Therapy and Secondary Prevention
ICD implantation within 40 days of myocardial infarction
ICD within 90 days of revascularization
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Unstable angina / non ST elevation myocardial infarction treatment On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Unstable angina / non ST elevation myocardial infarction treatment
CDC onUnstable angina / non ST elevation myocardial infarction treatment
Unstable angina / non ST elevation myocardial infarction treatment in the news
Blogs on Unstable angina / non ST elevation myocardial infarction treatment
to Hospitals Treating Unstable angina / non ST elevation myocardial infarction treatment
Risk calculators and risk factors for Unstable angina / non ST elevation myocardial infarction treatment

VisualWikitext

Revision as of 01:39, 16 July 2011

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]

Overview

Any recommendations found on these pages are for education use only. Wikidoc is not a substitute for a licensed healthcare provider. Please see the disclaimers page for important information regarding limitations of the information found here. In suggesting edits to the guidelines, Wikidoc suggests that the following classification scheme be used. Read more about the classification scheme used by the ACC / AHA Guidelines Committee here.

Revision as of 22:32, 9 July 2011 (view source) Lakshmi Gopalakrishnan (talk \| contribs) No edit summary ← Older edit	Revision as of 01:39, 16 July 2011 (view source) Lakshmi Gopalakrishnan (talk \| contribs) m (Unstable angina treatment moved to Unstable angina / non ST elevation myocardial infarction treatment) Newer edit →
(No difference)

Unstable angina / non ST elevation myocardial infarction treatment: Difference between revisions

Revision as of 01:39, 16 July 2011

Overview

Recommendations for Immediate Management [1] [2]

CLASS I

CLASS IIa

Recommendations for Anti Ischemic Therapy [1] [2]

CLASS I

CLASS IIa

CLASS IIb

CLASS III

Recommendations for Antiplatelet Therapy [1] [2]

CLASS I

CLASS IIa

CLASS IIb

CLASS III

Recommendations for Anticoagulant Therapy [1] [2]

CLASS I

CLASS IIa

Recommendations for Additional Management Considerations for Antiplatelet and Anticoagulant Therapy [1] [2]

CLASS I

CLASS IIa

CLASS IIb

CLASS III

Recommendations for PCI [1] [2]

CLASS I

CLASS IIa

CLASS IIb

CLASS III

Recommendations for CABG [1] [2]

CLASS I

CLASS IIa

CLASS IIb

CLASS III

Initial Conservative versus Initial Invasive Strategies [1] [2]

CLASS I

CLASS IIb

CLASS III

Risk Stratification Before Discharge [1] [2]

CLASS I

Recommendations for Medical Regimen and Use of Medications [1] [2]

CLASS I

Recommendations for Beta Blockers Therapy [1] [2]

CLASS I

CLASS IIa

Recommendations for Inhibition of the Renin-Angiotensin-Aldosterone System [1] [2]

CLASS I

CLASS IIa

CLASS IIb

Recommendations for Nitroglycerin Therapy [1] [2]

CLASS I

Recommendations for Calcium Channel Blockers Therapy [1] [2]

CLASS I

Recommendations for Warfarin Therapy [1] [2]

CLASS I

CLASS IIb

Recommendations for Lipid Management [1] [2]

CLASS I

CLASS IIa

CLASS IIb

Recommendations for Blood Pressure Control [1] [2]

CLASS I

Recommendations for Diabetes Mellitus Management [1] [2]

CLASS I

Recommendations for Smoking Cessation [1] [2]

CLASS I

Recommendations for Weight Management [1] [2]

CLASS I

Recommendations for Physical Activity [1] [2]

CLASS I

CLASS IIb

Recommendations for Patient Education [1] [2]

CLASS I

Recommendations for Influenza Vaccination [1] [2]

CLASS I

Recommendations for Depression [1] [2]

CLASS IIa

Recommendations for Non steroidal Anti-Inflammatory Drugs Use [1] [2]

CLASS I

CLASS IIa

Recommendations for Immediate Management ^[1] ^[2]

Recommendations for Anti Ischemic Therapy ^[1] ^[2]

Recommendations for Antiplatelet Therapy ^[1] ^[2]

Recommendations for Anticoagulant Therapy ^[1] ^[2]

Recommendations for Additional Management Considerations for Antiplatelet and Anticoagulant Therapy ^[1] ^[2]

Recommendations for PCI ^[1] ^[2]

Recommendations for CABG ^[1] ^[2]

Initial Conservative versus Initial Invasive Strategies ^[1] ^[2]

Risk Stratification Before Discharge ^[1] ^[2]

Recommendations for Medical Regimen and Use of Medications ^[1] ^[2]

Recommendations for Beta Blockers Therapy ^[1] ^[2]

Recommendations for Inhibition of the Renin-Angiotensin-Aldosterone System ^[1] ^[2]

Recommendations for Nitroglycerin Therapy ^[1] ^[2]

Recommendations for Calcium Channel Blockers Therapy ^[1] ^[2]

Recommendations for Warfarin Therapy ^[1] ^[2]

Recommendations for Lipid Management ^[1] ^[2]

Recommendations for Blood Pressure Control ^[1] ^[2]

Recommendations for Diabetes Mellitus Management ^[1] ^[2]

Recommendations for Smoking Cessation ^[1] ^[2]

Recommendations for Weight Management ^[1] ^[2]

Recommendations for Physical Activity ^[1] ^[2]

Recommendations for Patient Education ^[1] ^[2]

Recommendations for Influenza Vaccination ^[1] ^[2]

Recommendations for Depression ^[1] ^[2]

Recommendations for Non steroidal Anti-Inflammatory Drugs Use ^[1] ^[2]

Recommendations for Hormone Therapy ^[1] ^[2]

Recommendations for Antioxidant Vitamins and Folic Acid Use ^[1] ^[2]

Recommendations for Post discharge Follow-Up ^[1] ^[2]

Recommendations for Cardiac Rehabilitation ^[1] ^[2]

Recommendations for UA/NSTEMI in Diabetic Patients ^[1] ^[2]

Recommendations for UA/NSTEMI in Post CABG Patients ^[1] ^[2]

Recommendations for UA/NSTEMI in Elderly ^[1] ^[2]

Recommendations for UA/NSTEMI in Chronic Kidney Disease ^[1] ^[2]

Recommendations for UA/NSTEMI in Drug and Substance Abusers ^[1] ^[2]

Recommendations for Prinzmetal’s Angina ^[1] ^[2]

Recommendations for patients with Cardiovascular Syndrome X ^[1] ^[2]